A 71623

Product NameA 71623
CAS130408-77-4
MFC44H56N8O9
MW840.97
EINECS
MOL File130408-77-4.mol

Chemical Properties

Boiling point	1126.589±65.00 °C(Press: 760.00 Torr)(predicted)
Density	1.287±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
storage temp.	Desiccate at -20°C
solubility	Soluble to 1 mg/ml in 20mM PBS buffer
form	solid
pka	4.383±0.10(predicted)
color	White

Usage And Synthesis

Uses

A-71623 is a potent CCK agonist with 1200-fold selectivity over the CCK2 receptor.

Biological Activity

Potent CCK 1 agonist (IC 50 = 3.7 nM) with 1200-fold selectivity over the CCK 2 receptor. Suppresses food intake following central or peripheral administration.

in vivo

A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats^[2].
A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck^-/- and Pcp2-AXTN1[82Q] mice^[3].
A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice^[3].

Animal Model:	Adult male, Sprague-Dawley rats^[2]
Dosage:	5 μL
Administration:	Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s
Result:	Reduced food intakes and suppressed intakes of a liquid diet.

Animal Model:	ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice ^[3]
Dosage:	0.02 mg/kg/day
Administration:	Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.)
Result:	Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck^-/- mice and ATXN1[82Q] mice. Improved motor performance in ATXN2[127Q] mice.

IC 50

CCKAR

storage

Store at -20°C

References

[1]. gracey dj, bell r, king dj. differential effects of the ccka receptor ligands pd-140,548 and a-71623 on latent inhibition in the rat. progress in neuro-psychopharmacology and biological psychiatry, 2002, 26(3): 497-504.
[2]. lin cw, shiosaki k, miller tr, et al. characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, a-71623 and a-70874, that exhibit high potency and selectivity for cholecystokinin-a receptors. molecular pharmacology, 1991, 39(3): 346-351.
[3]. kaufmann r, lindschau c, scho t, et al. type b cholecystokinin receptors on rat glioma c6 cells. binding studies and measurement of intracellular calcium mobilization. brain research, 1994, 639(1): 109-114.

A 71623 Supplier

Related Product Information

Send Inquriy